STE · STERIS plc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q1 FY27 earnings call · Aug 6, 2026TL;DR. STERIS (STE) reported fiscal Q1 2027 results with revenue up 7%, constant currency organic growth of 6%, and adjusted EPS of $2.59 (up 11%), while reiterating full-year revenue and EPS guidance and announcing a $600M North Carolina chemistry Center of Excellence that lowers free cash flow guidance to $800M from $850M and raises fiscal 2027 CapEx to $450M.
- + Q1 revenue grew 7% with constant currency organic growth of 6%
- + Q1 adjusted EPS rose 11% to $2.59
- + Gross margin expanded 70 bps and EBIT margin expanded 100 bps
- + Announced $600M North Carolina chemistry Center of Excellence to scale high-growth, high-margin business
- − FY27 free cash flow guidance lowered to $800M from $850M
- − FY27 CapEx raised to ~$450M from $375M due to North Carolina investment
- − Q1 free cash flow fell to $279.6M from $326.5M on weaker working capital
- − Adjusted effective tax rate jumped to 25.9% from 23.5%
- − AST EBIT margin contracted 60 bps to 48% on higher depreciation and lower productivity
- − Life Sciences EBIT margin fell 140 bps to 42.1% on unfavorable productivity and inflation
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AST segment operating margin | 48% | the first three months of fiscal 2027 filing | — |
| Capital expenditures | $87.5M | the first three months of fiscal 2027 filing | — |
| Debt-to-total capital ratio | 20.9% | the three months ended June 30, 2026 filing | — |
| Free cash flow non-GAAP | $279.6M | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 367.1M
-87.5M Purchases of property, plant, equipment, and intangibles, net
+0M Proceeds from the sale of property, plant, equipment, and intangibles
= Free cash flow 279.6M
|
|||
| Healthcare segment operating margin | 24.8% | the first three months of fiscal 2027 filing | — |
| Life Sciences segment operating margin | 42.1% | the first three months of fiscal 2027 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STE
this stock
STERIS plc
|
$20.37B | -17.4% | +8.7% | 26.4 | 2.9% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.8% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.0% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -22.3% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.7% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STE | +0.3% | -9.1% | -6.0% | -0.3% | -17.4% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +0.7% | -9.0% | -18.4% | -0.5% | -29.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.